Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
donanemab
Pharma
NICE again rejects Alzheimer's drugs from Lilly and Biogen/Eisai
After reviewing additional clinical data, England's NICE has slapped down Eli Lilly's Kisunla and Biogen and Eisai's Leqembi for a second time.
Kevin Dunleavy
Mar 6, 2025 10:47am
Lawmakers spotlight studies run at China military hospitals
Aug 20, 2024 2:34pm
Lilly execs chart launch of Alzheimer's newcomer Kisunla
Jul 11, 2024 11:03am
Game on: Lilly's Alzheimer's drug Kisunla gains FDA nod
Jul 2, 2024 2:33pm
Analysts tip Lilly's Alzheimer's launch to boost rival Leqembi
Jun 12, 2024 9:29am
Lilly tipped to beat Eisai, Biogen, win $13B Alzheimer's fight
Jun 7, 2024 4:51am
